A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NBI-56418 in Endometriosis
收藏DataCite Commons2024-12-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005296/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with subjects randomized to one of three treatment groups, placebo, 75 mg and 150 mg in a 1:1:1 ratio. Study drug was administered once daily for 12 weeks. After the last dose at the end of Week 12, follow-up continued every 4 weeks for 12 weeks.
提供机构：
Vivli
创建时间：
2020-03-03
